Peritoneum and tissues of the female reproductive tract as physiological sources of CA-125

被引：36

作者：

Zeimet, AG

Offner, FA

Muller-Holzner, E

Widschwendter, M

Abendstein, B

Fuith, LC

Daxenbichler, G

Marth, C

机构：

[1] Univ Innsbruck, Dept Obstet & Gynecol, A-6020 Innsbruck, Austria

[2] Univ Innsbruck, Dept Pathol, A-6020 Innsbruck, Austria

[3] Gen Hosp, Dept Obstet & Gynecol, Eisenstadt, Austria

[4] Norwegian Radium Hosp, Dept Gynecol Oncol, Oslo, Norway

[5] Gen Hosp, Dept Obstet & Gynecol, Hall In Tirol, Austria

来源：

TUMOR BIOLOGY | 1998年 / 19卷 / 04期

关键词：

CA-125; tumor marker; menstrual cycle; endometrium; ovary; mesothelial cells; ovarian surface epithelium; cytokines;

D O I：

10.1159/000030018

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The origin of physiological CA-125 serum levels, which in normally menstruating women were shown to depend on their actual menstrual cycle phase, has not yet been completely elucidated. It is furthermore conceivable that physiological CA-125 sources may contribute to serum elevations in the various pathologies associated with increased circulating CA-125. The present review deals with menstrual cycle-dependent expression of CA-125 in normal tissues of the female reproductive tract in relation to the actual circulating CA-125 levels together with in vivo data concerning the inductive effect of medroxyprogesterone acetate on circulating CA-125 studied in 24 postmenopausal women. Furthermore, in vitro results on constitutive, steroid hormone- and cytokine-modulated CA-125 shedding from human peritoneal mesothelial and ovarian surface epithelial cells are summarized.

引用

页码：275 / 282

页数：8

共 25 条

[1]

BARBIERI RL, 1986, FERTIL STERIL, V45, P630

[2] CA-125 (OVARIAN TUMOR-ASSOCIATED ANTIGEN) IN ASCITIC LIVER-DISEASES [J].

BERGMANN, JF ;

BEAUGRAND, M ;

LABADIE, H ;

BIDART, JM ;

BOHUON, C .

CLINICA CHIMICA ACTA, 1986, 155 (02) :163-165

[3]

BERGMANN JF, 1987, CANCER-AM CANCER SOC, V59, P213, DOI 10.1002/1097-0142(19870115)59:2<213::AID-CNCR2820590206>3.0.CO

[4]

2-I

[5]

DALLENBACHHELLW.G, 1984, ATLAS ENDOMETRIAL HI, P12

[6]

GROVER S, 1992, OBSTET GYNECOL, V79, P511

[7]

HALILA H, 1986, CANCER, V57, P1327, DOI 10.1002/1097-0142(19860401)57:7<1327::AID-CNCR2820570713>3.0.CO

[8]

2-Z

[9] CA-125 IN PERITONEAL-FLUID AND SERUM FROM PATIENTS WITH BENIGN GYNECOLOGIC CONDITIONS AND OVARIAN-CANCER [J].

HUNTER, VJ ;

WEINBERG, JB ;

HANEY, AF ;

SOPER, JT ;

LAVIN, P ;

METSCH, L ;

KNAPP, RC ;

BAST, RC .

GYNECOLOGIC ONCOLOGY, 1990, 36 (02) :161-165

[10]

JAGER W, 1988, FERTIL STERIL, V50, P223

← 1 2 3 →